| Literature DB >> 22284801 |
Gabriel Kaplan1, James T McCracken.
Abstract
At present, no evidence-based effective pharmacologic options are available for treating the core deficits of autism spectrum disorders (ASDs), which are best addressed by behavioral and educational interventions. However, such evidence exists for several of the frequently associated/comorbid symptoms such as aggression and severe irritability, hyperactivity, and repetitive behaviors, which can become a major source of additional distress and interference in functioning. This article offers information on the psychopharmacology of ASD that is current, relevant, and organized in a user-friendly manner, to form a concise but informative reference guide for primary pediatric clinicians.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22284801 DOI: 10.1016/j.pcl.2011.10.005
Source DB: PubMed Journal: Pediatr Clin North Am ISSN: 0031-3955 Impact factor: 3.278